The University of Glasgow’s Glasgow Precision Oncology Laboratory (GPOL) is a molecular research facility that partners with the UK’s NHS and industry to perform research into the development of novel therapeutic strategies, the creation of pan-cancer genomic assays and provide knowledge transfer for healthcare systems to enable them to develop landscapes for therapeutic testing in cancer.
Attributes | Values |
---|
rdfs:label
| - Glasgow Precision Oncology Laboratory (en)
|
rdfs:comment
| - The University of Glasgow’s Glasgow Precision Oncology Laboratory (GPOL) is a molecular research facility that partners with the UK’s NHS and industry to perform research into the development of novel therapeutic strategies, the creation of pan-cancer genomic assays and provide knowledge transfer for healthcare systems to enable them to develop landscapes for therapeutic testing in cancer. (en)
|
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
has abstract
| - The University of Glasgow’s Glasgow Precision Oncology Laboratory (GPOL) is a molecular research facility that partners with the UK’s NHS and industry to perform research into the development of novel therapeutic strategies, the creation of pan-cancer genomic assays and provide knowledge transfer for healthcare systems to enable them to develop landscapes for therapeutic testing in cancer. GPOL’s integrated structure is designed to take scientific ideas through preclinical studies to translation into the clinic. GPOL combines research expertise in targeted capture and whole-genome sequencing, cancer bioinformatics and the development of patient pathways in precision oncology in routine healthcare. GPOL performs tests for discovery work on patient tumours, including whole-genome sequencing and RNA-seq, and experiments to understand models of disease, particularly genetically engineered mouse models, by defining their genomic mutational landscapes and transcriptome, and providing molecular phenotypes for clinical trials development in oncology. GPOL uses international data, including that collected by the International Cancer Genome Consortium (ICGC), The Cancer Genome Atlas and Pan-Cancer Analysis of Whole Genomes (PCAWG), to create the suite of Glasgow Cancer Assays (also known as the Glasgow Cancer Test and the Clinical Cancer Genome) – standardised pan-cancer assays covering adult solid tumours and haematological cancers for use by healthcare systems and researchers worldwide. The Glasgow Cancer Assays are currently in use for testing patients for clinical trials but, with the aim of incorporating the test in routine healthcare as part of a learning healthcare system (LHS,) are being evaluated by the UK’s NHS and a network of cancer centres in Italy. The Glasgow Cancer Assays are licensed to Agilent Technologies on a non-exclusive basis for global distribution for research. (en)
|
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
foaf:isPrimaryTopicOf
| |
is foaf:primaryTopic
of | |